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Our group recently employed genome-wide transcriptional proﬁling in tandem with machine-learning based
analysis to identify a ten-gene pattern of diﬀerential expression in peripheral blood which may have utility for
detection of stroke. The objective of this study was to assess the diagnostic capacity and temporal stability of this
stroke-associated transcriptional signature in an independent patient population. Publicly available whole blood
microarray data generated from 23 ischemic stroke patients at 3, 5, and 24 h post-symptom onset, as well from
23 cardiovascular disease controls, were obtained via the National Center for Biotechnology Information Gene
Expression Omnibus. Expression levels of the ten candidate genes (ANTXR2, STK3, PDK4, CD163, MAL, GRAP,
ID3, CTSZ, KIF1B, and PLXDC2) were extracted, compared between groups, and evaluated for their discriminatory ability at each time point. We observed a largely identical pattern of diﬀerential expression between
stroke patients and controls across the ten candidate genes as reported in our prior work. Furthermore, the
coordinate expression levels of the ten candidate genes were able to discriminate between stroke patients and
controls with levels of sensitivity and speciﬁcity upwards of 90% across all three time points. These ﬁndings
conﬁrm the diagnostic robustness of the previously identiﬁed pattern of diﬀerential expression in an independent patient population, and further suggest that it is temporally stable over the ﬁrst 24 h of stroke pathology.

1. Introduction
The ability of clinicians to conﬁdently recognize stroke during
triage increases access to interventional treatments and aﬀords patients
improved odds for favorable outcome [1,2]. However, the diagnostic
tools currently available to emergency medical technicians, paramedics, and hospital staﬀ for identiﬁcation of stroke have signiﬁcant
limitations [3,4]. Biomarker-based tests are clinically used to aid in the
diagnosis of acute cardiovascular conditions such as myocardial infarction [5], however no such assay currently exists for the detection of
stroke. This diagnostic limitation has resulted in a push for the identiﬁcation of peripheral blood stroke biomarkers which could be rapidly
measured in either the ﬁeld or emergency department to guide early
triage decisions [3,6].
Our group recently employed high-throughput transcriptomics in

⁎

combination with a machine learning technique known as genetic algorithm/k-nearest neighbors (GA/kNN) to identify a panel of ten candidate genes whose peripheral blood expression levels were able to
diﬀerentiate between 78 ischemic stroke patients and 74 control subjects with a high degree of accuracy [7]. These candidate genes include
seven whose expression levels were elevated in stroke patients relative
to controls (CD163, ANTXR2, PDK4, PLXDC2, STK3, ID3, CTSZ, KIF1B),
and three whose expression levels were down regulated (MAL, ID3,
GRAP); their coordinate pattern of diﬀerential expression was able to
discriminate between groups with levels of sensitivity and speciﬁcity
approaching 100%. While the levels of diagnostic performance observed in this discovery investigation were unprecedented, limitations
in study design necessitate further evaluation of the candidate genes in
a validation analysis before deﬁnitive conclusions can be made regarding their true diagnostic eﬃcacy.
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under curves were then compared between time points via the roc.test()
function according the non-parametric method described by DeLong
et al. [18].

Stroke patients and control subjects in this discovery investigation
were not well matched in terms of cardiovascular disease (CVD) risk
factors, leaving open the possibility that the pattern of diﬀerential expression which we observed across the ten candidate genes was driven
by underlying CVD, and not by the acute event of stroke itself.
Furthermore, subjects in this discovery study were almost exclusively
Caucasian, and it is currently unknown whether ethnicity impacts the
diagnostic eﬃcacy the candidate genes, a possibility which deserves
consideration due to the fact that there can be notable inter-ethnic
diﬀerences in the pathophysiology of cardiovascular conditions [8–11].
A further limitation in of this discovery study was the fact that blood
samples were only collected at a single time point, making the temporal
stability of candidate gene diﬀerential expression unclear with regards
to the progression of stroke pathology. While post hoc statistical analyses were used to address these potential confounds as best possible, it
would be reassuring to observe similar levels of diagnostic performance
across multiple time points in a more ethnically diverse subject pool
which is better matched in terms of CVD risk factors.
Stamova et al. recently used microarray to examine gender diﬀerences in the response of the peripheral immune system to stroke [12].
This investigation produced a publicly available data set which includes
genome-wide whole blood expression data generated from 23 cardioembolic ischemic stroke patients at three replicate time points postsymptom onset (3, 5, and 24 h), as well as from 23 neurologically
asymptomatic control subjects; this patient population was ethnically
diverse and groups were well matched in terms of risk factors for CVD.
In the study reported here, we assessed the diagnostic robustness of the
ten previously identiﬁed candidate genes in the aforementioned publicly available data set.

2.4. Statistics
All statistics were performed using R 3.3. Fisher's exact test was
used for comparison of dichotomous variables. t-Test or one-way
ANOVA was used for comparisons of continuous variables where appropriate. The null hypothesis was rejected when p < 0.05. In the case
of multiple comparisons, p-values were false discovery rate adjusted
using the Benjamini-Hochberg procedure [19].
3. Results
3.1. Clinical and demographic characteristics
Stroke patients were signiﬁcantly older than control patients, but
well matched in terms of gender and ethnicity. In terms of cardiovascular disease risk factors, groups were well matched with regards to
rates of hypertension and diabetes, however control subjects displayed
a signiﬁcantly higher prevalence of dyslipidemia relative to stroke patients. All stroke patients received thrombolytic intervention via recombinant tissue plasminogen activator (rtPA) following 3 h blood
collection, but prior to 5 h blood collection (Table 1).
3.2. Microarray data processing
Distributions of perfect match probe intensities were visually similar
following normalization, providing indication that normalized expression data were suitable for inter-sample comparison (Fig. 1). Probe sets
extracted for diﬀerential expression analysis are listed in Table 2.

2. Methods
2.1. Data procurement

3.3. Candidate gene diﬀerential expression
Raw whole blood microarray data (Aﬀymetrix Human Genome
U133 Plus 2.0 Array) were downloaded as .CEL ﬁles from the National
Center for Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO) via accession number GSE58294 (Supplementary File 1). Patient
clinical and demographic characteristics were aggregated from the
gender-wise information reported by Stamova et al. [12].

Six of the seven candidate genes which we had previously reported
as being elevated in stroke in our prior investigation displayed similar
up-regulation in stroke patients relative to controls (Fig. 2A, B, D, E, F,
J), however one exhibited no signiﬁcant diﬀerences in expression levels
at any time point post-symptom onset (Fig. 2H). In terms of the candidate genes which we had previously reported as being down regulated in stroke, all three displayed signiﬁcantly lower expression levels
in stroke patients relative to controls (Fig. 2C, G, I). Collectively, these
observations largely conﬁrmed the pattern of candidate gene diﬀerential expression reported in our prior investigation.

2.2. Microarray analysis
Analysis of microarray data was performed using the ‘aﬀy’ package
for R (R project for statistical computing) [13,14]. Raw perfect match
probe intensities were background corrected, quantile normalized
(Fig. 1), and summarized at the set level via robust multi-array averaging using the rma() function [15]. Probe set level data associated
with the ten candidate genes were then extracted for diﬀerential expression analysis; in the case of candidate genes with more than one
associated probe set, data were further summarized at the gene level via
simple averaging. Gene level summarized expression levels were then
compared between stroke patients and controls across all three postonset time points.

3.4. Temporal proﬁle of candidate diﬀerential expression
Most candidate genes displayed some degree of diﬀerential expression by 3 h post-symptom onset, and the magnitude of the overall
response appeared to increase over time. Several candidate genes appeared to achieve maximal diﬀerential expression at 5 h post-onset and
then plateau, while a few displayed steady increases in the degree of
diﬀerential expression through 24 h (Fig. 3), providing evidence that
the expression levels of the candidate genes are likely directly responsive to acute stroke pathology.

2.3. Diagnostic evaluation
The diagnostic robustness of candidate gene expression levels was
tested in terms of their ability to discriminate between stroke patients
and controls using k-nearest neighbors (kNN) at each time point postsymptom onset. Classiﬁcation was performed using standardized expression values, ﬁve nearest neighbors, and majority rule via the knn.cv
() function of the ‘class’ package for R [16]. Same-set leave one out
cross-validation was performed, and the resultant prediction probabilities were used to generate receiver operator characteristic (ROC)
curves using the roc() function of the ‘pROC’ package for R [17]. Areas

3.5. Candidate gene diagnostic performance
In terms of diagnostic ability, the coordinate expression levels of the
ten candidate genes were able to discriminate between stroke patients
and controls using kNN with levels of sensitivity and speciﬁcity upwards of 90% at all three time points post-symptom onset (Fig. 4A, B,
C). While the overall diagnostic capacity of the ten candidate genes
appeared slightly more robust at ﬁve and 24 h, no statistically signiﬁcant diﬀerences in area under ROC curve were observed between
48
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Fig. 1. Normalization of microarray data.
Distributions of pre and post-normalization perfect match probe intensities. Boxplots indicate standard ﬁve number summary values.

Table 1
Clinical and demographic characteristics.

a

Age mean ± SD
Female n(%)
b
Non-caucasian n(%)
b
Dyslipidemia n(%)
b
Hypertension n(%)
b
Diabetes n(%)
b

Table 2
Probe sets extracted for diﬀerential expression analysis.

Cardiovascular
disease (n = 23)

Ischemic stroke
(n = 23)

p

57.9 ± 3.3
11 (47.8)
4 (17.4)
16 (69.6)
16 (69.6)
5 (21.7)
0.0 ± 0.0

57.9 ± 7.9
11 (47.8)
8 (34.8)
6 (26.1)
16 (69.6)
4 (17.4)
15.4 ± 7.4

< 0.001⁎
1.000
0.314
0.007⁎
1.000
1.000
< 0.001⁎

0 (0.0)

23 (100.0)

< 0.001⁎

Gene

Aﬀy probe set ID

Target transcriptsa

CD163

203645_s_at
215049_x_at
216233_at

ANTXR2

1555536_at
225524_at
228573_at
238050_at
204777_s_at

NM_004244
NM_203416
XM_005253528
XM_005253529
XR_429039
NM_001145794
NM_001286780
NM_001286781
NM_058172
NM_002371
NM_022438
NM_022439
NM_022440
NM_002612
NM_001282736
NM_032812

a

b

Baseline NIHSS
mean ± SD
rtPA n(%)

a
b
⁎

MAL

Compared via two sample two way t-test.
Compared via Fisher's exact test.
Statistically signiﬁcant.

PDK4
PLXDC2

time points (Fig. 4D). Taken together, these observations supported the
high levels of diagnostic performance reported in our prior work, and
suggest that the diagnostic capacity of the ten candidate genes is temporally stable over the ﬁrst 24 h post-symptom onset.

STK3

4. Discussion

ID3
CTSZ

There has been a recent push for the identiﬁcation of molecular
biomarkers which could be used to aid clinicians in the recognition of
stroke during patient triage. Our group recently employed highthroughput transcriptomics in combination with a machine-learning
technique known at GA/kNN to identify a ten gene pattern of diﬀerential expression in peripheral blood which has potential utility for the
detection of stroke [7]. However, patients in this discovery investigation were almost exclusively Caucasian, groups were not well matched
in terms of CVD risk factors, and blood was only sampled at a single
time point post-symptom onset. In the study reported here, we leveraged a publicly available microarray dataset to evaluate the previously
identiﬁed candidate pattern of gene expression at multiple pathological
time points in a more ethnically diverse subject pool which was better
matched in terms of CVD risk factors.
The overall pattern of diﬀerential expression which we previously
reported between stroke patients and controls was largely conﬁrmed in
the analysis described here, as nine of the ten candidate genes were

GRAP

KIF1B

a

205960_at
214807_at
226865_at
227276_at
227995_at
236297_at
238455_at
204068_at
211078_s_at

207826_s_at
210042_s_at
212562_s_at
206620_at
229726_at
209234_at
225878_at
226968_at
228657_at

NM_001256312
NM_001256313
NM_006281
XM_005251034
NM_002167
NM_001336
NM_006613
XM_005256425
XM_005256426
NM_015074
NM_183416

NCBI RefSeq ID.

identically diﬀerentially regulated. Furthermore, the candidate genes
displayed similar levels of diagnostic robustness as described previously. This suggests that it is unlikely that our prior ﬁndings were
substantially driven by intergroup diﬀerences in CVD risk factors; this
notion is accentuated by the fact that the overall pattern of diﬀerential
expression across the ten candidate genes was temporally dynamic with
regards to time from symptom onset, providing evidence that the
49
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Fig. 2. Candidate gene diﬀerential expression.
(A–J) Peripheral whole blood expression levels of candidate genes in stroke patients and controls at 3, 5, and 24 h post-symptom onset. Expression values represent gene-level summarized Log2 perfect match probe intensities. Expression levels were statistically compared between stroke patients and controls across time points using one-way AVOVA; p-values were
false discovery rate adjusted via the Benjamini-Hochberg procedure to account for multiple comparisons. In the case of a signiﬁcant test, post hoc comparisons were made via two-sample
two-tailed t-test.

candidate genes are directly responsive to stroke pathology. The fact
that our prior observations were largely recapitulated in the analysis
reported here also suggests that ethnicity likely has little inﬂuence on
the overall transcriptional response of the candidate genes to stroke.
One possible exception with this regard is CTSZ, which was the only
candidate gene which failed to exhibit a similar response to stroke as
previously reported. Thus, it is possible that the diﬀerential regulation
of CTSZ which we observed in our discovery investigation was indeed
driven primarily by underlying CVD, or that there are interethnic differences in the responsiveness of CTSZ to stroke. However, to our
knowledge, there are no associations reported in the literature to support either conclusion, and is possible that the discrepancy in response
between investigations has other explanation. The samples analyzed in
this study were obtained exclusively from patients presenting with ischemic strokes of cardioembolic etiology, while the samples used in our
prior discovery study were obtained from patients presenting with ischemic strokes of multiple etiologies, including a large number which
were thrombotic in nature; thus it is possible that the disagreement in
ﬁndings is due to an etiology-speciﬁc response. The disagreement in
ﬁndings could also be driven by a technical confound, as the gene expression data used in this analysis were generated using a diﬀerent gene
chip then that which was used in our discovery investigation, and the
chips do not have completely overlapping transcriptional coverage of
CTSZ.
In addition to providing a general validation of the overall pattern

Fig. 3. Temporal proﬁle of candidate gene diﬀerential expression.
Magnitude of candidate gene diﬀerential expression between stroke patients and controls
at 3, 5, and 24 h post-symptom onset, indicated as fold diﬀerence relative to control.
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Fig. 4. Candidate gene diagnostic performance.
(A–C) Two-dimensional projections of the kNN feature spaces generated by the coordinate expression levels of the ten candidate genes at 3, 5, and 24 h post-symptom onset. Levels of
sensitivity and speciﬁcity are associated with class predications generated via ﬁve nearest neighbors using a probability cutoﬀ of 0.50. (D) ROC curves associated with the prediction
probabilities generated in kNN. Shaded areas indicate 95% conﬁdence intervals. Areas under curves were statistically compared between time points using the DeLong method.

the two investigations (Illumina versus Aﬀymetrix) and accurate crossplatform normalization is diﬃcult. Nonetheless, this does not diminish
the fact that we observed a highly identical pattern of diﬀerential expression across the candidate markers as reported in our prior discovery
investigation, which provides compelling evidence that these makers
are reliably altered in stroke pathology and have true potential for
clinical biomarker use.
However, for such clinical use to be realized, there are several
further developmental hurdles which need to be overcome. Most notable from this regard is the development of an assay which could
measure these markers rapidly and accurately at the point of care with
minimal specimen processing, which would be essential for triage use in
the acute care setting. Unfortunately, a commercially available platform capable of rapid nucleic acid quantiﬁcation with high enough ﬁdelity to detect relatively modest levels of diﬀerential expression, such
as those we have described across the candidate markers, does not
currently exist. However, research into rapid detection of nucleic acids
is ongoing, and promising new advances such as those regarding direct
RNA nanodetection and thermoneutral ampliﬁcation suggest that suitable technologies will be available in the near future [20–22].
Collectively, the ﬁndings of this analysis conﬁrm the diagnostic
robustness of the previously identiﬁed stroke-associated pattern of gene
expression, and further suggest that it is temporally stable over the ﬁrst
24 h of stroke pathology. Due to fact that this transcriptional signature
has now demonstrated levels of diagnostic performance which well
exceed those of the triage tools currently available to clinicians for
identiﬁcation of stroke in two independent investigations, we feel that
it has legitimate translational potential and a path towards clinical
implementation should be further explored.

of candidate gene diﬀerential expression, this study also aﬀorded us an
opportunity to evaluate its temporal stability with regards to stroke
pathophysiology. The overall pattern of diﬀerential expression was
modestly detectable at 3 h post-symptom onset and appeared to increase in magnitude though 24 h. Despite the modest magnitude, the
levels of diﬀerential expression present at 3 h post-onset were still
adequate to diﬀerentiate between groups with similarly high levels of
diagnostic performance as those observed at the subsequent two time
points. Overall, our ﬁndings suggested that the diagnostic ability of the
candidate pattern of gene expression is relatively temporally stable over
the ﬁrst 24 h of stroke pathophysiology, which is encouraging from a
translational standpoint in that the ﬁrst clinical contact with stroke
patients tends to vary across a wide time range with regards to time
from onset, depending in the overtness of symptom presentation.
It is relevant to note that the 5 and 24 h blood samples which we
analyzed in this study were collected from stroke patients following
thrombolytic intervention, leaving open the possibility that the diﬀerential expression which we observed across the candidate genes at these
time points was driven by the eﬀect of rtPA, and not the ischemic event
itself. However, we ﬁnd this unlikely, as the diﬀerential expression
pattern which we observed was highly similar to the one reported in
our previous discovery investigation in which all blood samples were
collected prior to the administration of thrombolytics. Furthermore, the
fact we have now observed a similar pattern of diﬀerential expression
both before and following thrombolytic intervention suggests that the
response of the candidate markers is not largely inﬂuenced by rtPA; this
property leaves open the possibility that the candidate markers could be
clinically useful not only for triage, but also for non-acute post-treatment indications, such as to molecularly conﬁrm pathology as means of
determining clinical trial eligibility.
A potential limitation with regards to this study lies in that the
stroke patients and controls associated with the samples used in this
analysis were not well matched in terms of age. Ideally, multiple regression could be used to statistically control for such a potential confound, however non-aggregated demographic information was not
available for the dataset, making such an analysis impossible. However,
we explored the relationship between the expression levels of the ten
candidate genes and age as part of our previously reported discovery
investigation, and observed no signiﬁcant associations. Thus, we feel
that it is unlikely that the results reported here are confounded by intergroup age diﬀerences.
It is also important to note that a signiﬁcant translational limitation
in our analysis lies in that we built and tested a de novo classiﬁcation
model using only the candidate gene expression data contained in the
dataset generated by stamova et al. Ideally, the classiﬁcation model we
generated in our previously-published discovery analysis could have
been tested in the Stamova et al. dataset, however this was infeasible
due to the fact that diﬀerent microarray platforms were used between
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